Zhejiang Huahai Pharmaceutical's (SHA:600521) U.S. subsidiary Solco Healthcare received tariff refunds of $14.2 million after the Supreme Court ruled tariffs imposed by the Trump administration under the International Emergency Economic Powers Act were invalid, according to a Thursday filing with the Shanghai bourse.
The tariff refund represents 36% of the most recent audited net profit and could increase 2026 net profit by 96.9 million yuan.